RELMADA THERAPEUT.DL-001

Research RELMADA THERAPEUT.DL-001 (4E2) with Bullrun company financials, valuation charts, model signals, and historical stock context.

Key Metrics

• Ticker4E2
• ExchangeF
• CountryUnited States
• CurrencyEUR

About RELMADA THERAPEUT.DL-001

Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer;

Frequently asked questions

What does RELMADA THERAPEUT.DL-001 do?

Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of...